Open AccessClinical and immunological effect of subcutaneous immunotherapy in allergic asthma
Author(s) -
Eman O. Arram,
Aida M. Yousef,
Amal Fathy,
Ahmed Atwa
Publication year - 2017
Publication title -
egyptian journal of chest diseases and tuberculosis/egyptian journal of chest diseases and tuberculosis
Language(s) - English
Resource type - Journals
eISSN - 2090-9950
pISSN - 0422-7638
DOI - 10.1016/j.ejcdt.2016.10.004
Subject(s) - medicine , exacerbation , asthma , immunoglobulin e , immunotherapy , immunology , allergy , allergen immunotherapy , allergen , immune system , antibody
Background: Allergen immunotherapy is a potentially curative treatment approach in allergic diseases, subcutaneous immunotherapy is therapeutic option in treatment of allergic asthma.Aim of the study: In the present study, subcutaneous immunotherapy (SCIT) using multiple allergen was administered to allergic asthmatic patients without allergic rhinitis or mixed allergy aiming to evaluate its efficacy, safety and evaluate the changes in the immune response.Patients and methods: The study included 56 patients with allergic asthma alone, all patients received SCIT according to the results of skin prick test over a period of 1 year, initial clinical evaluation including the presence of exacerbation and need of inhalers treatment, pulmonary function tests were performed also total immunoglobulin E(IgE), immunoglobulin A(IgA) and leukotriene C4(LTC4) were measured and repeated after 1 year of initiation of the course of SCIT.Results: There were highly significant clinical improvement as regard exacerbation presence, need for inhalers and improvement of the forced expiratory volume in the first second FEV1 also there were highly significant decrease in total IgE, LTC4 and highly significant increase of IgA, after one year of SCIT.Conclusion: SCIT is a safe treatment strategy that significantly reduce exacerbation and medication requirement in allergic asthma without mixed allergy also improve immunological response